This company has been marked as potentially delisted and may not be actively trading. IMARA (IMRA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock IMRA vs. ALKS, ZLAB, AKRO, RYTM, PBH, CYTK, PTCT, RNA, MRUS, and SRPTShould you be buying IMARA stock or one of its competitors? The main competitors of IMARA include Alkermes (ALKS), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Rhythm Pharmaceuticals (RYTM), Prestige Consumer Healthcare (PBH), Cytokinetics (CYTK), PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Merus (MRUS), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry. IMARA vs. Its Competitors Alkermes Zai Lab Akero Therapeutics Rhythm Pharmaceuticals Prestige Consumer Healthcare Cytokinetics PTC Therapeutics Avidity Biosciences Merus Sarepta Therapeutics IMARA (NASDAQ:IMRA) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and earnings. Which has more volatility and risk, IMRA or ALKS? IMARA has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Do analysts prefer IMRA or ALKS? Alkermes has a consensus price target of $38.85, indicating a potential upside of 30.23%. Given Alkermes' stronger consensus rating and higher probable upside, analysts clearly believe Alkermes is more favorable than IMARA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMARA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alkermes 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.77 Does the media prefer IMRA or ALKS? In the previous week, Alkermes had 9 more articles in the media than IMARA. MarketBeat recorded 10 mentions for Alkermes and 1 mentions for IMARA. Alkermes' average media sentiment score of 0.96 beat IMARA's score of 0.00 indicating that Alkermes is being referred to more favorably in the news media. Company Overall Sentiment IMARA Neutral Alkermes Positive Which has preferable earnings and valuation, IMRA or ALKS? Alkermes has higher revenue and earnings than IMARA. Alkermes is trading at a lower price-to-earnings ratio than IMARA, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMARAN/AN/A$1.49M$0.05982.05Alkermes$1.51B3.25$367.07M$2.0914.27 Do institutionals and insiders believe in IMRA or ALKS? 49.3% of IMARA shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 37.3% of IMARA shares are owned by insiders. Comparatively, 4.4% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is IMRA or ALKS more profitable? Alkermes has a net margin of 23.57% compared to IMARA's net margin of 0.00%. Alkermes' return on equity of 30.80% beat IMARA's return on equity.Company Net Margins Return on Equity Return on Assets IMARAN/A 2.12% 2.00% Alkermes 23.57%30.80%19.09% Does the MarketBeat Community prefer IMRA or ALKS? Alkermes received 680 more outperform votes than IMARA when rated by MarketBeat users. Likewise, 70.18% of users gave Alkermes an outperform vote while only 57.78% of users gave IMARA an outperform vote. CompanyUnderperformOutperformIMARAOutperform Votes2657.78% Underperform Votes1942.22% AlkermesOutperform Votes70670.18% Underperform Votes30029.82% SummaryAlkermes beats IMARA on 15 of the 18 factors compared between the two stocks. Get IMARA News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRA vs. The Competition Export to ExcelMetricIMARAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$6.88B$5.57B$8.50BDividend YieldN/A2.48%5.27%4.17%P/E Ratio982.258.4626.7519.66Price / SalesN/A261.91403.98152.07Price / Cash75.2465.8538.2534.64Price / Book14.276.526.964.59Net Income$1.49M$143.26M$3.23B$248.23M IMARA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRAIMARAN/A$49.10-3.3%N/AN/A$1.29BN/A982.2541Insider TradeALKSAlkermes4.6852 of 5 stars$31.06-0.3%$38.85+25.1%+21.8%$5.12B$1.51B14.312,280Insider TradeZLABZai Lab1.2665 of 5 stars$40.00+5.6%$47.37+18.4%+119.4%$4.41B$418.33M-14.441,950Analyst RevisionGap UpAKROAkero Therapeutics3.6098 of 5 stars$54.52-0.3%$82.50+51.3%+131.9%$4.35BN/A-14.5430Trending NewsInsider TradeGap DownRYTMRhythm Pharmaceuticals4.151 of 5 stars$67.37+1.0%$76.62+13.7%+47.1%$4.29B$136.86M-15.56140Insider TradePBHPrestige Consumer Healthcare4.1103 of 5 stars$86.59+1.1%$93.33+7.8%+30.3%$4.28B$1.14B20.28540Positive NewsCYTKCytokinetics4.2618 of 5 stars$34.54+4.3%$70.92+105.3%-36.3%$4.13B$19.22M-6.42250Analyst RevisionPTCTPTC Therapeutics3.869 of 5 stars$51.74+0.1%$63.75+23.2%+43.1%$4.10B$1.77B-8.711,410Analyst RevisionGap DownRNAAvidity Biosciences1.9283 of 5 stars$33.62+2.9%$67.50+100.8%-20.9%$4.05B$8.93M-11.67190Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionGap DownMRUSMerus3.1031 of 5 stars$56.45+2.8%$85.83+52.1%-3.4%$3.91B$54.73M-14.2937SRPTSarepta Therapeutics4.7004 of 5 stars$39.07-1.6%$122.61+213.8%-70.5%$3.84B$2.23B31.26840 Related Companies and Tools Related Companies Alkermes Alternatives Zai Lab Alternatives Akero Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Prestige Consumer Healthcare Alternatives Cytokinetics Alternatives PTC Therapeutics Alternatives Avidity Biosciences Alternatives Merus Alternatives Sarepta Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRA) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMARA Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMARA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
